Iodide

Iodide

SCHEMBL7051892

C[n+]1ccc(C#N)cc1.[I-]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 7/20 0.95
CYP2A6 P11509 2/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.43
CHAT P28329 1/20 0.40
CA12 O43570 1/20 0.40
CA2 P00918 1/20 0.40
CA3 P07451 1/20 0.40
CA6 P23280 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
PABPC1 P11940 1/20 0.39
APOBEC3A P31941 1/20 0.39
EIF4H Q15056 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
SLC22A2 O15244 1/20 0.39
SLC22A1 O15245 1/20 0.39
SLC22A3 O75751 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL23131037 1.00 HDAC8 (0.95) HDAC8CYP2A6ALDH1A1TSHRCHAT
SCHEMBL5455838 0.97
Hydrochloric Acid SCHEMBL5831783 0.95 HDAC8 (0.95) HDAC8CYP2A6ALDH1A1TSHRCA12
Iodide SCHEMBL23131038 0.95 HDAC8 (0.95) HDAC8CYP2A6ALDH1A1TSHRCHAT
SCHEMBL23131039 0.88 HDAC8 (0.82) HDAC8CYP2A6ALDH1A1TSHRCHAT
SCHEMBL31034828 0.84 HDAC8 (0.75) HDAC8CYP2A6ALDH1A1TSHRCA2
SCHEMBL6238003 0.80 HDAC8 (0.67) HDAC8CYP2A6ALDH1A1TSHRCHAT
SCHEMBL577736 0.80 HDAC8 (0.67) HDAC8CYP2A6ALDH1A1TSHRCA12
SCHEMBL5483989 0.78 HDAC8 (0.64) HDAC8CYP2A6ALDH1A1CA12CA2
SCHEMBL5487286 0.75 HDAC8 (0.60) HDAC8CYP2A6ALDH1A1TSHRCHAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10961224-B2 Triazinium cation forms and methods of making thereof LOYOLA UNIVERSITY NEW ORLEANS (US) 2021-03-30 US claimed
WO-2018183749-A1 TRIAZINIUM CATION FORMS AND METHODS OF MAKING THEREOF LOYOLA UNIVERSITY NEW ORLEANS (US) 2018-10-04 WO claimed
US-20030034480-A1 Conversion of non-conducting polymers to conducting polymers BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS, THE 2003-02-20 US claimed
WO-2001051994-A1 CONVERSION OF NON-CONDUCTING POLYMERS TO CONDUCTING POLYMERS THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) 2001-07-19 WO claimed
US-4758312-A Adding colorless electrochemically active compound having positive reduction potential NALCO CHEMICAL COMPANY (US) 1988-07-19 US claimed
JP-55142050-A None JP disclosed
EP-4414359-A1 CATALYTIC PROCESS FOR THE PREPARATION OF AMIDES Università di Pisa (IT) 2024-08-14 EP disclosed
US-10961224-B2 Triazinium cation forms and methods of making thereof LOYOLA UNIVERSITY NEW ORLEANS (US) 2021-03-30 US disclosed
WO-2018183749-A1 TRIAZINIUM CATION FORMS AND METHODS OF MAKING THEREOF LOYOLA UNIVERSITY NEW ORLEANS (US) 2018-10-04 WO disclosed
US-20030034480-A1 Conversion of non-conducting polymers to conducting polymers BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS, THE 2003-02-20 US disclosed
EP-0174632-B1 ANTI-MICROBIAL N-(1-(ALKYL OR ARYLMETHYL)-4(1H)-PYRIDINYLIDINE)ALKANAMINES AND ACID ADDITION SALTS THEREOF AND PROCESS FOR PREPARATION, METHODS OF USE AND COMPOSITIONS THEREOF STERLING DRUG INC. (US) 1990-02-07 EP disclosed
US-4839372-A ANTIPLAQUE AGENTS STERLING DRUG INC. (US) 1989-06-13 US disclosed
US-4758312-A Adding colorless electrochemically active compound having positive reduction potential NALCO CHEMICAL COMPANY (US) 1988-07-19 US disclosed
EP-0237738-A2 Method for in situ corrosion detection using electrochemically active compounds NALCO CHEMICAL COMPANY (US) 1987-09-23 EP disclosed
US-4683035-A Method for in situ corrosion detection using electrochemically active compounds NALCO CHEMICAL COMPANY (US) 1987-07-28 US disclosed
US-4598082-A DENTISTRY STERLING DRUG INC. (US) 1986-07-01 US disclosed
EP-0174632-A1 Anti-microbial N-(1-(alkyl or arylmethyl)-4(1H)-pyridinylidine)alkanamines and acid addition salts thereof and process for preparation, methods of use and compositions thereof STERLING DRUG INC. (US) 1986-03-19 EP disclosed
JP-S55142050-A LACQUER COMPOSITION FOR HIGHLY DIELECTRIC FILM MATSUSHITA ELECTRIC IND CO LTD 1980-11-06 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961224-B2 Triazinium cation forms and methods of making thereof MITF, SOD1, TYR HDAC8 2288/4885CYP2A6 2600/4885ALDH1A1 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.